Why Did Hims & Hers Stock Surge? Cheaper Wegovy Alternative Announced

Hims & Hers Health, Inc. (NYSE: HIMS) experienced a dramatic stock surge on Thursday, February 5, 2026, jumping over 10% in trading after the telehealth platform announced a major expansion of its weight loss portfolio. The company revealed plans to offer compounded versions of semaglutide pills, the same active ingredient found in Novo Nordisk’s popular Wegovy medication, at a fraction of the brand-name price.

This strategic move positions Hims & Hers as a significant disruptor in the weight loss drug market, offering patients needle-free alternatives at unprecedented affordability. The announcement sent shockwaves through the pharmaceutical industry, with Novo Nordisk shares tumbling approximately 5-7% on the news.

Cheaper Wegovy Alternative Sparks Investor Interest

Hims & Hers announced that eligible customers can access compounded semaglutide pills starting at just $49 for the first month as part of a special introductory offer. This represents a substantial discount, approximately $100 less, compared to Novo Nordisk’s branded Wegovy pill, which retails at $149 for a 30-day supply.

After the introductory period, patients with a 5-month subscription plan can continue treatment at $99 per month, still significantly cheaper than Novo Nordisk’s $199 monthly charge for ongoing treatment. Shorter subscription options are also available, including a 3-month plan totaling $277.

The compounded semaglutide pill uses the same active ingredient as Wegovy but employs a different formulation and delivery system. According to the company, the pill is specially formulated to protect the active ingredient during digestion and support optimal absorption.

This needle-free treatment option is designed to appeal to patients who are averse to injections or seeking to manage side effects through personalized dosing. Dr. Craig Primack, Head of Weight Loss at Hims & Hers, emphasized that the platform now supports “a deeper level of personalization” by giving providers more options to tailor treatments to individual patient needs.

Hims & Hers has been steadily building its weight loss business, already offering compounded versions of injectable semaglutide medications. The company doubled its facility footprint in 2025 to over one million square feet, integrating advanced pharmacy capabilities, lab testing, and research and development space.

CEO Andrew Dudum stated that the company has “spent years building the infrastructure required to put the power of choice back into the hands of the individual,” emphasizing their commitment to providing providers with multiple safe options for patient care.

Join our Telegram group and never miss a breaking digital asset story.

Stock Surge and Fallout Across Weight-Loss Drug Makers

As of 9:59 AM EST on February 5, 2026, HIMS stock was trading at $26.81, up $2.46 or 10.08% from the previous close of $24.35. The stock opened significantly higher at $26.80 and reached an intraday high of $27.77, with trading volume surging to over 18 million shares, exceeding the average daily volume of 17.5 million.

The market capitalization stood at approximately $6.137 billion, reflecting strong investor enthusiasm for the company’s competitive pricing strategy in the weight loss medication market.

The stock has experienced considerable volatility in recent months, with a 52-week range spanning from $23.97 to $72.98. Year-to-date, HIMS shares had been down 16.95% prior to Thursday’s announcement, and the 1-year return showed a decline of 36.10%.

However, the longer-term picture remains positive, with a 3-year return of 241.77% significantly outperforming the S&P 500’s 65.48% gain over the same period. Analysts maintained an average price target of $39.69 for the stock, with estimates ranging from $25 to $68.

The announcement had immediate ripple effects across the pharmaceutical sector. Novo Nordisk (NYSE: NVO) shares fell approximately 5-7%, extending a multi-day selloff that began after the company issued a disappointing outlook earlier in the week, citing unprecedented pricing pressure in the weight loss drug market. Eli Lilly (NYSE: LLY), another major player in GLP-1 medications, also declined 3.6% on the news.

The market reaction underscored investor concerns about intensifying competition and pricing pressures facing established pharmaceutical manufacturers as telehealth platforms and compounding pharmacies offer increasingly affordable alternatives to branded weight loss medications.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.